Related Experiment Video

Updated: May 1, 2026

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

6.6K

Optimizing outcomes for paediatric atopic dermatitis

L F Eichenfield1, C Totri

  • 1Pediatric and Adolescent Dermatology, Rady Children's Hospital, San Diego, CA, U.S.A; School of Medicine, University of California, San Diego, CA, U.S.A.

The British Journal of Dermatology
|April 12, 2014
PubMed

Insights

Atopic dermatitis (AD) affects nearly 20% of children, characterized by skin barrier dysfunction and infections. Improved understanding guides treatment, but more research is needed on optimal outcome measures for clinical trials.

Area of Science:

  • Pediatric dermatology
  • Immunology
  • Genetics

Background:

  • Atopic dermatitis (AD) is a prevalent chronic inflammatory skin condition in young children, affecting up to 20% in industrialized nations.
  • Recent research highlights genetically determined skin barrier dysfunction and microbial infections as key factors in AD exacerbations.
  • Current management relies on topical anti-inflammatories and emollients, requiring parental education on application and safety concerns.

Purpose of the Study:

  • To review current understanding of atopic dermatitis (AD) in children.
  • To discuss the role of skin barrier dysfunction and microbial infections in AD pathogenesis.
  • To identify optimal outcome measures for future clinical trials in pediatric AD.

Main Methods:

  • Review of recent advances in understanding AD etiology and pathogenesis.
  • Analysis of current therapeutic approaches for pediatric AD.
  • Discussion on the importance of outcome measures in clinical trials.

Main Results:

  • Genetically determined skin barrier defects and microbial infections significantly influence AD.
  • Topical corticosteroids, calcineurin inhibitors, and emollients are standard treatments.
  • Parental education and reassurance regarding treatment are crucial.

Conclusions:

  • Further research is essential to define the best clinical outcome measures for pediatric AD trials.
  • Improving the long-term control of AD flares and quality of life remains a key objective.
  • Enhanced understanding of AD pathogenesis informs treatment strategies for young patients.

More Related Videos

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

38.4K
Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment06:47

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment

Published on: September 27, 2017

9.3K

Related Concept Videos

Acne Infection01:27

Acne Infection

Acne is a multifactorial skin condition primarily affecting adolescents and young adults, with a global prevalence estimated to exceed 75% in this demographic. The condition is characterized by the formation of comedones (blackheads and whiteheads), papules, pustules, nodules, and, in severe cases, cysts, particularly in areas rich in sebaceous glands such as the face, neck, chest, and back. The pathogenesis involves increased sebum production, follicular hyperkeratinization, colonization by...
94
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
408
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
967
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
410
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
1.0K
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
554